Advertisement

Molecular Diagnosis & Therapy

, Volume 20, Issue 2, pp 125–133 | Cite as

Effect of Cysteamine on Mutant ASL Proteins with Cysteine for Arginine Substitutions

  • Corinne Inauen
  • Véronique Rüfenacht
  • Amit V. Pandey
  • Liyan Hu
  • Henk Blom
  • Jean-Marc Nuoffer
  • Johannes HäberleEmail author
Short Communication

Abstract

Introduction

Cysteamine is used to treat cystinosis via the modification of cysteine residues substituting arginine in mutant proteins.

Objectives

We investigated the effect of cysteamine on mutant argininosuccinate lyase (ASL), the second most common defect in the urea cycle.

Methods

In an established mammalian expression system, 293T cell lysates were produced after transfection with all known cysteine for arginine mutations in the ASL gene (p.Arg94Cys, p.Arg95Cys, p.Arg168Cys, p.Arg379Cys, and p.Arg385Cys), allowing testing of the effect of cysteamine over 48 h in the culture medium as well as for 1 h immediately prior to the enzyme assay.

Results

Cysteamine at low concentrations showed no effect on 293T cell viability, ASL protein expression, or ASL activity when applied during cell culture. However, incubation of transfected cells with 0.05 mM cysteamine immediately before the enzyme assay resulted in increased ASL activity of p.Arg94Cys, p.Arg379Cys, and p.Arg385Cys by 64, 20, and 197 %, respectively, and this result was significant (p < 0.01). Cell lysates carrying p.Arg385Cys and treated with cysteamine recover enzyme activity that is similar to the untreated designed mutation p.Arg385Lys, providing circumstantial evidence for the assumed cysteamine-induced change of a cysteine to a lysine analogue.

Conclusion

Since 12 % of all known genotypes in ASL deficiency are affected by a cysteine for arginine mutation, we conclude that the potential of cysteamine or of related substances as remedy for this disease should be investigated further.

Keywords

293T Cell Cysteamine Cystinosis Urea Cycle Disorder Transfected 293T Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Compliance with Ethical Standards

Conflict of interest

The authors CI, VR, AVP, LH, HB, JMN, and JH declare that they have no conflicts of interest.

Funding

This work was supported by the Swiss National Science Foundation (Grants 310030_153196/1 to JH and 310031_134926 to AVP) and a grant from Schweizerische Mobiliar Genossenschaft Jubiläumsstiftung to AVP.

Supplementary material

40291_2015_182_MOESM1_ESM.tif (50 kb)
Supplementary material 1 (TIFF 50 kb)
40291_2015_182_MOESM2_ESM.docx (26 kb)
Supplementary material 2 (DOCX 25 kb)

References

  1. 1.
    Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. BMJ. 1995;311(7020):1621–5.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Häberle J, Shahbeck N, Ibrahim K, Schmitt B, Scheer I, O’Gorman R, et al. Glutamine supplementation in a child with inherited GS deficiency improves the clinical status and partially corrects the peripheral and central amino acid imbalance. Orphanet J Rare Dis. 2012;7:48. doi: 10.1186/1750-1172-7-48.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Wood J, Sames L, Moore A, Ekins S. Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery. Drug Discov Today. 2013;18(21–22):1043–51. doi: 10.1016/j.drudis.2013.08.006.CrossRefPubMedGoogle Scholar
  4. 4.
    Gahl WA, Gregg RE, Hoeg JM, Fisher E. In vivo alteration of a mutant human protein using the free thiol cysteamine. Am J Med Genet. 1985;20(2):409–17. doi: 10.1002/ajmg.1320200226.CrossRefPubMedGoogle Scholar
  5. 5.
    Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 1982;257(5):2518–21.PubMedGoogle Scholar
  6. 6.
    Aly AM, Arai M, Hoyer LW. Cysteamine enhances the procoagulant activity of Factor VIII-East Hartford, a dysfunctional protein due to a light chain thrombin cleavage site mutation (arginine-1689 to cysteine). J Clin Invest. 1992;89(5):1375–81. doi: 10.1172/JCI115725.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hoagland MB, Novelli GD. Biosynthesis of coenzyme A from phospho-pantetheine and of pantetheine from pantothenate. J Biol Chem. 1954;207(2):767–73.PubMedGoogle Scholar
  8. 8.
    Besouw M, Masereeuw R, van den Heuvel L, Levtchenko E. Cysteamine: an old drug with new potential. Drug Discov Today. 2013;18(15–16):785–92. doi: 10.1016/j.drudis.2013.02.003.CrossRefPubMedGoogle Scholar
  9. 9.
    Thoene JG, Oshima RG, Crawhall JC, Olson DL, Schneider JA. Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo. J Clin Invest. 1976;58(1):180–9. doi: 10.1172/JCI108448.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med. 2002;347(2):111–21. doi: 10.1056/NEJMra020552.CrossRefPubMedGoogle Scholar
  11. 11.
    Pisoni RL, Thoene JG, Christensen HN. Detection and characterization of carrier-mediated cationic amino acid transport in lysosomes of normal and cystinotic human fibroblasts. Role in therapeutic cystine removal? J Biol Chem. 1985;260(8):4791–8.PubMedGoogle Scholar
  12. 12.
    Summar ML, Koelker S, Freedenberg D, Le Mons C, Häberle J, Lee HS, et al. The incidence of urea cycle disorders. Mol Genet Metab. 2013;110(1–2):179–80. doi: 10.1016/j.ymgme.2013.07.008.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Balmer C, Pandey AV, Rüfenacht V, Nuoffer JM, Fang P, Wong LJ, et al. Mutations and polymorphisms in the human argininosuccinate lyase (ASL) gene. Hum Mutat. 2014;35(1):27–35. doi: 10.1002/humu.22469.CrossRefPubMedGoogle Scholar
  14. 14.
    Hu L, Pandey AV, Balmer C, Eggimann S, Rüfenacht V, Nuoffer JM, et al. Unstable argininosuccinate lyase in variant forms of the urea cycle disorder argininosuccinic aciduria. J Inherit Metab Dis. 2015;38(5):815–27. doi: 10.1007/s10545-014-9807-3.CrossRefPubMedGoogle Scholar
  15. 15.
    Hu L, Pandey AV, Eggimann S, Rüfenacht V, Moslinger D, Nuoffer JM, et al. Understanding the role of argininosuccinate lyase transcript variants in the clinical and biochemical variability of the urea cycle disorder argininosuccinic aciduria. J Biol Chem. 2013;288(48):34599–611. doi: 10.1074/jbc.M113.503128.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Engel K, Vuissoz JM, Eggimann S, Groux M, Berning C, Hu L, et al. Bacterial expression of mutant argininosuccinate lyase reveals imperfect correlation of in-vitro enzyme activity with clinical phenotype in argininosuccinic aciduria. J Inherit Metab Dis. 2012;35(1):133–40. doi: 10.1007/s10545-011-9357-x.CrossRefPubMedGoogle Scholar
  17. 17.
    Sampaleanu LM, Vallee F, Thompson GD, Howell PL. Three-dimensional structure of the argininosuccinate lyase frequently complementing allele Q286R. Biochemistry. 2001;40(51):15570–80.CrossRefPubMedGoogle Scholar
  18. 18.
    Turner MA, Simpson A, McInnes RR, Howell PL. Human argininosuccinate lyase: a structural basis for intragenic complementation. Proc Natl Acad Sci USA. 1997;94(17):9063–8.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Krieger E, Darden T, Nabuurs SB, Finkelstein A, Vriend G. Making optimal use of empirical energy functions: force-field parameterization in crystal space. Proteins. 2004;57(4):678–83.CrossRefPubMedGoogle Scholar
  20. 20.
    Vriend G. WHAT IF: a molecular modeling and drug design program. J Mol Graph. 1990;8(1):52–6, 29.Google Scholar
  21. 21.
    Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–61. doi: 10.1002/jcc.21334.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model. 2011;51(10):2778–86. doi: 10.1021/ci200227u.CrossRefPubMedGoogle Scholar
  23. 23.
    Linnebank M, Tschiedel E, Häberle J, Linnebank A, Willenbring H, Kleijer WJ, et al. Argininosuccinate lyase (ASL) deficiency: mutation analysis in 27 patients and a completed structure of the human ASL gene. Hum Genet. 2002;111(4–5):350–9. doi: 10.1007/s00439-002-0793-4.CrossRefPubMedGoogle Scholar
  24. 24.
    Kleijer WJ, Garritsen VH, Linnebank M, Mooyer P, Huijmans JG, Mustonen A, et al. Clinical, enzymatic, and molecular genetic characterization of a biochemical variant type of argininosuccinic aciduria: prenatal and postnatal diagnosis in five unrelated families. J Inherit Metab Dis. 2002;25(5):399–410.CrossRefPubMedGoogle Scholar
  25. 25.
    Cooper DN, Youssoufian H. The CpG dinucleotide and human genetic disease. Hum Genet. 1988;78(2):151–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Mancini D, Singh S, Ainsworth P, Rodenhiser D. Constitutively methylated CpG dinucleotides as mutation hot spots in the retinoblastoma gene (RB1). Am J Hum Genet. 1997;61(1):80–7. doi: 10.1086/513898.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Brawer JR, Reichard G, Small L, Schipper HM. The origin and composition of peroxidase-positive granules in cysteamine-treated astrocytes in culture. Brain Res. 1994;633(1–2):9–20 (pii:0006-8993(94)91516-4).CrossRefPubMedGoogle Scholar
  28. 28.
    Jezegou A, Llinares E, Anne C, Kieffer-Jaquinod S, O’Regan S, Aupetit J, et al. Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter underlying the action of cysteamine in cystinosis therapy. Proc Natl Acad Sci USA. 2012;109(50):E3434–43. doi: 10.1073/pnas.1211198109.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Wan XM, Zheng F, Zhang L, Miao YY, Man N, Wen LP. Autophagy-mediated chemosensitization by cysteamine in cancer cells. Int J Cancer. 2011;129(5):1087–95. doi: 10.1002/ijc.25771.CrossRefPubMedGoogle Scholar
  30. 30.
    Smolin LA, Clark KF, Thoene JG, Gahl WA, Schneider JA. A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine in nephropathic cystinosis. Pediatr Res. 1988;23(6):616–20. doi: 10.1203/00006450-198806000-00018.CrossRefPubMedGoogle Scholar
  31. 31.
    Hua Long L, Halliwell B. Oxidation and generation of hydrogen peroxide by thiol compounds in commonly used cell culture media. Biochem Biophys Res Commun. 2001;286(5):991–4. doi: 10.1006/bbrc.2001.5514.
  32. 32.
    Yudkoff M, Daikhin Y, Ye X, Wilson JM, Batshaw ML. In vivo measurement of ureagenesis with stable isotopes. J Inherit Metab Dis. 1998;21(Suppl 1):21–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Corinne Inauen
    • 1
  • Véronique Rüfenacht
    • 1
  • Amit V. Pandey
    • 2
  • Liyan Hu
    • 1
    • 3
  • Henk Blom
    • 4
  • Jean-Marc Nuoffer
    • 5
    • 6
  • Johannes Häberle
    • 1
    • 3
    • 7
    Email author
  1. 1.Division of Metabolism and Children’s Research Centre (CRC)University Children’s Hospital ZürichZurichSwitzerland
  2. 2.Pediatric Endocrinology, University Children’s Hospital and Department of Clinical ResearchUniversity of BernBernSwitzerland
  3. 3.Affiliated with the Neuroscience Center Zürich (ZNZ)ZurichSwitzerland
  4. 4.Department of General Pediatrics, Adolescent Medicine and NeonatologyUniversity Medical Centre FreiburgFreiburgGermany
  5. 5.University Institute of Clinical ChemistryUniversity of BernBernSwitzerland
  6. 6.University Children’s HospitalUniversity of BernBernSwitzerland
  7. 7.Affiliated with the Zürich Center for Integrative Human Physiology (ZIHP)ZurichSwitzerland

Personalised recommendations